Document is current
Any future updates will be listed below
-
Authors
Atkinson, Elizabeth G. http://orcid.org/0000-0002-6308-776X
Maihofer, Adam X. http://orcid.org/0000-0003-4517-1623
Kanai, Masahiro http://orcid.org/0000-0001-5165-4408
Martin, Alicia R. http://orcid.org/0000-0003-0241-3522
Karczewski, Konrad J. http://orcid.org/0000-0003-2878-4671
Santoro, Marcos L. http://orcid.org/0000-0001-5714-9509
Ulirsch, Jacob C. http://orcid.org/0000-0002-7947-0827
Kamatani, Yoichiro
Okada, Yukinori http://orcid.org/0000-0002-0311-8472
Finucane, Hilary K. http://orcid.org/0000-0003-3864-9828
Koenen, Karestan C.
Nievergelt, Caroline M. http://orcid.org/0000-0001-5766-8923
Daly, Mark J.
Neale, Benjamin M. http://orcid.org/0000-0003-1513-6077
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (K01MH121659, T32MH017119)
Heiwa Nakajima Foundation
Masason Foundation
Fundação de Amparo à Pesquisa do Estado de São Paulo (#2018/09328-2)
Ministry of Education, Culture, Sports, Science and Technology
Japan Agency for Medical Research and Development
- License Information
-
More Information
Article History
Received: 15 May 2020
Accepted: 15 December 2020
First Online: 18 January 2021
Competing interests
: M.J.D. is a founder of Maze Therapeutics. A.R.M. serves as a consultant for 23andMe and is a member of the Precise.ly Scientific Advisory Board. B.M.N. is a member of the Deep Genomics Scientific Advisory Board and serves as a consultant for the CAMP4 Therapeutics Corporation, Takeda Pharmaceutical and Biogen. The remaining authors declare no competing interests.
